We’ve had to watch the devastating symptoms of heart failure as the disease progresses and the damage becomes irreversible.

Cardiac Dimensions is on a mission to bring more success to the treatment of heart failure patients.

A completely different and much earlier approach to treating functional mitral regurgitation (FMR) than any other device therapy currently available to patients.

The goal: Treat the condition—not just the symptoms.

The Carillon System is designed to work with the natural structure and function of the heart to help treat the condition of FMR as well as the related symptoms.

We believe the Carillon Therapy is a smarter solution to help patients feel better and live longer lives.

The Carillon Therapy is a good option for our patients. According to published research, there’s a demonstrated positive relationship between the Carillon Therapy and improving the quality-of-life metrics our patients care about.

Heart failure is a progressive disease. It’s an expensive disease. It’s a devastating disease. Over 20% of heart failure patients with FMR die within the first year of diagnosis and 50% die within five years.1 Each year thousands of these patients find the disease has advanced and their options extremely limited.

Cardiac Dimensions’ mission is to give new hope to those suffering from heart failure so they can live longer, higher quality lives.

We’re harnessing our science, technology, and talent to take on this global crisis and improve the survivability for heart failure patients with FMR. Our goal is to treat patients earlier in the disease process—when it’s needed.

And by uniquely treating the underlying causes—not just symptoms.

We are a privately held company headquartered in Kirkland, Washington with operations in the United States, Australia, and Germany.